Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect
  • NCT03989414

Recruiting

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - CC-92480-MM-002

Oppdatert: 8 januar, 2024   |   ClinicalTrials.gov

Celgene er et heleid datterselskap av Bristol-Myers Squibb 

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.
Skriv ut denne siden CC-92480-MM-002
Last ned Veiledning for studiedeltakere

VELG SPRÅK

Vis detaljer

  • Phase 1/Phase 2

    Fase

  • Kjønn

  • 18+

    Aldersgruppe

  • 26

    Sted(er)

  • Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: CC-92480 in combination with bortezomib and dexamethasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: CC-92480 in combination with carfilzomib and dexamethasone
Drug: Elotuzumab, CC-92480, Dexamethasone
Experimental: CC-92480 in combination with daratumumab and dexamethasone
Drug: Dexamethasone, Carfilzomib, CC-92480
Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
Drug: Carfilzomib, CC-92480, Dexamethasone
Experimental: Cohort E: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Dexamethasone, Elotuzumab
Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Cohort H: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort I: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort J: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort K: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone

Nøkkelkriterier for kvalifikasjon

Inclusion Criteria: 1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen. 3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma. 4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan. Exclusion Criteria: 1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046